Urticaria treated with dapsone

@article{Boehm1999UrticariaTW,
  title={Urticaria treated with dapsone},
  author={Ingrid Boehm and Ralf Bauer and Thomas Bieber},
  journal={Allergy},
  year={1999},
  volume={54}
}
Evidence of both symptomatic and curative effects of low-dose 4,4'-diaminodiphenylsul-fone in a case of therapy-refractory chronic idiopathic urticaria (CIU). 

Topics from this paper

Prospective randomized non‐blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria
  • B. Engin, M. Özdemir
  • Medicine
  • Journal of the European Academy of Dermatology and Venereology : JEADV
  • 2008
TLDR
The once-in-a-lifetime treatment of chronic idiopathic urticaria with or without steroids is still a viable option and may help improve the prognosis. Expand
Low-dose dapsone in chronic idiopathic urticaria: preliminary results of an open study.
TLDR
The cumulative experience with dapsone in some cases of severe refractory CIU is presented, and it is shown that this drug has the potential to improve the quality of life of patients with CIU. Expand
Treatment of chronic urticaria.
Second-generation antihistamines are unquestionably the first-line treatment for chronic urticaria and can be used at higher than licensed doses if normal doses fail to control the disease. A shortExpand
Evidence for methotrexate as a useful treatment for steroid-dependent chronic urticaria.
TLDR
Methotrexate is an effective and safe treatment for chronic urticaria in patients who are not responsive to conventional therapy, and five out of the 7 patients were disease-free during a period of 1-10 months follow-up after discontinuing methotrexate and prednisone therapy. Expand
Therapy of chronic urticaria: a simple, modern approach.
  • A. Kaplan
  • Medicine
  • Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2014
TLDR
Omalizumab has exceptional efficacy for antihistamine-resistant CSU with an excellent adverse effect profile. Expand
Alternative agents in refractory chronic urticaria: evidence and considerations on their selection and use.
  • D. Khan
  • Medicine
  • The journal of allergy and clinical immunology. In practice
  • 2013
TLDR
Although numerous knowledge gaps exist for alternative agents in refractory CU, a rational, patient-based approach can be used with a goal of improving control and quality of life and minimizing adverse medication effects. Expand
Treatment of Severely Recalcitrant Chronic Spontaneous Urticaria: A Discussion of Relevant Issues
TLDR
A case of a female patient with CSU who, despite taking 15 antihistamines a day in addition to a number of second-line therapies, continued to be refractory to treatment, but once she initiated subcutaneous treatment with omalizumab 300 mg every 4 weeks, she experienced rapid relief of her CSU symptoms. Expand
Therapeutic Perspectives on the Treatment of Urticaria Associated with
TLDR
Treatment of urticaria is not easy and when angioedema associated therapeutic measures should be complex, non-sedating H 1 -antihistamines are considered first-line treatment. Expand
Use of Dapsone in the Treatment of Chronic Idiopathic and Autoimmune Urticaria
TLDR
Results of this study suggest that dapsone is a useful and well-tolerated second-line therapy for patients with CSU in whom antihistamines and other first-line agents have failed. Expand
Update on the treatment of chronic urticaria.
TLDR
Although guidelines call for increasing the dosage when response is inadequate, some patients still do not achieve adequate control of symptoms, and new treatment alternatives must therefore be developed. Expand
...
1
2
3
4
...

References

SHOWING 1-4 OF 4 REFERENCES
Urticaria. Recognition, causes and treatment.
TLDR
For the majority of patients with chronic idiopathic urticaria, nonsedating antihistamines are the mainstay of treatment, and recent work on circulating histamine releasing autoantibodies suggests that there is scope for more aggressive immunosuppression in selected patients. Expand
Intravenous immunoglobulin in autoimmune chronic urticaria
TLDR
IVIG represents a novel therapeutic option in selected patients with recalcitrant CU associated with histamine releasing autoantibodies and diminution in urticarial activity in the majority of patients corresponded with a reduced weal‐and‐flare response to the intradermal injection of autologous post‐treatment serum compared with the pretreatment serum. Expand
β2‐integrins in different forms of urticaria
As urticarial lesions involve tissue invasion by inflammatory cells, and as β2‐integrins play a central part in adhesion of leucocytes to endothelia, allowing their migration into the tissues, weExpand
Chronic urticaria: pathophysiology and treatment approaches.
  • M. Tharp
  • Medicine
  • The Journal of allergy and clinical immunology
  • 1996
TLDR
During the introduction of antihistamine and anti-polymorphonuclear neutrophil therapy, a simultaneous brief course of systemic corticosteroid therapy may be necessary, but the extended use of systemic Corticosteroids should be avoided because of significant adverse effects. Expand